THE EFFECT OF LOW-DOSE OKT3 MONOCLONAL-ANTIBODY THERAPY ON K562 CYTOTOXICITY IN HUMAN CANCER-PATIENTS
Low concentrations of monoclonal antibodies (mAb) specific for the CD3 component of the T cell receptor complex (TcR) may be both immunosuppressive or potent activators of T cell function in vitro depending upon the experimental situation. The anti-CD3 mAb OKT3 is imnmunosuppressive
at high doses (5 mg/day for 10 to 14 days) in transplant patients. We undertook a preliminary study to investigate the effect of a single intravenous injection of 50 mu g to 0.5 mu g of OKT3 mAb in cancer patients. OKT3 modulated cytotoxicity with minimal clinical toxicity at low doses and
may be of use in cancer immunotherapy protocols.
Document Type: Research Article
Affiliations: UNIV LEICESTER,LEICESTER ROYAL INFIRM,SCH MED,DEPT SURG,LEICESTER LE2 7LX,ENGLAND.
Publication date: 01 September 1994
- The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content